Track AstraZeneca PLC — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

AstraZeneca PLC ZEG.F · Stock Open AstraZeneca PLC in new tab

142.40 EUR
P/E
24.55
EPS
5.72
Yield
1.93%
P/B
5.25
ROE
21.97
Beta
0.21
Loading chart...
Key Metrics
P/E24.55
EPS5.72
Book Value26.76
Price to Book5.25
Debt/Equity64.23
% Insiders0.047%
Growth
Revenue Growth0.06%
Earnings Growth0.03%
Dividend
Dividend Yield1.93%
Annual dividends2.77 EUR
Ex-Div. DateAug. 6, 2026
Payout47.41%
5y avg Yield2.09%

DCF Valuation

Tweak assumptions to recompute fair value for AstraZeneca PLC (ZEG.F)
Currency: EUR
DCF Assumptions
Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).
Decimal (e.g., 0.30 = 30%).
Decimal (e.g., 0.04 = 4%).
Decimal (e.g., 0.20 = 20%).
Percent number (e.g., 3 = 3%).
Percent number (e.g., 10 = 10%).
Percent number (e.g., 5 = 5%).
DCF Result

Fair Value (DCF)
Current Price
Upside
WACC
Terminal PV
Σ PV of FCFs
Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

AstraZeneca PLC Logo AstraZeneca PLC Analysis (ZEG.F)

United Kingdom Health Care Official Website Stock

Is AstraZeneca PLC a good investment? AstraZeneca PLC (ZEG.F) is currently trading at 142.40 EUR.

In terms of valuation, the stock trades at a P/E ratio of 24.55. This valuation is generally in line with the broader market.

For income investors, AstraZeneca PLC pays a dividend yield of 1.93%. With a payout ratio of 47%, the dividend appears sustainable.

Investor FAQ

Does AstraZeneca PLC pay a dividend?

Yes, it pays an annual dividend of 2.77 EUR (1.93% yield).

What asset class is AstraZeneca PLC?

AstraZeneca PLC is classified as a Stock. You can compare it against 17 other assets in the "Related Symbols" list on this page.

Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splendil, Munobal, Flodil, Tenormin, Tenormine, Prenormine, Atenol, Zestril, Brilinta/Brilique, Komboglyze, Qtern, Wainua, Byetta, Lokelma, Seloken ZOK, Toprol-XL, Betaloc ZOK, XIGDUO, Accolate, Accoleit, Vanticon, Bricanyl Respules, Eklira Genuair/Tudorza/Bretaris, Pulmicort Turbuhaler, Symbicort Turbuhaler, Airsupra, Bricanyl Turbuhaler, Fasenra, Rhinocort, Tezspire, Bevespi Aerosphere, Daliresp/Daxas, Oxis Turbuhaler, Saphnelo, Breztri Aerosphere, Duaklir Genuair, Pulmicort Respules, and Symbicort pMDI. It also provides Beyfortus, Kavigale, Evusheld, Fluenz/FluMist, Synagis, Kanuma, Ultomiris, Koselugo, Voydeya, Soliris, Strensiq, Nexium, and other medicines. The company offers its products for ocology, cardiovascular, renal and metabolism, respiratory & immunology, vaccines and immune, and therapies rare diseases. It serves primary and specialty care physicians through distributors and local representative offices in the United Kingdom, the Americas, rest of Europe, Asia, Africa, and Australasia. It has a strategic agreement with Tempus and Pathos to develop the largest multimodal foundation model in oncology; CSPC Pharmaceutical Group Limited to advance the discovery and development of novel oral candidates, with the potential to treat diseases across multiple indications; and Nucs AI Inc. to develop AI-driven Response Prediction for Therapeutic Radioconjugates. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

Exchange Ticker
MEX (Mexico) AZNN.MX
BUE (Argentina) AZN.BA
GER (Germany) ZEG.DE
MIL (Italy) UV4L0Q.MI
BER (Germany) ZEG.BE
DUS (Germany) ZEG.DU
HAN (Germany) ZEG.HA
FRA (Germany) ZEGA.F
STU (Germany) ZEGA.SG
FRA (Germany) ZEG.F
HAM (Germany) ZEG.HM
MUN (Germany) ZEG.MU
STU (Germany) ZEG.SG
NMS (United States) AZN
PNK (United States) AZNCF
LSE (United Kingdom) AZN.L
STO (Sweden) AZN.ST
Trades
Dividend Yield
1.93%
5y avg 2.09%
Annual Dividends
2.77EUR
Next Ex. Div Date
Aug. 6, 2026
Payout Ratio
47.41%
Dividend History paid per year (EUR)
Historical Dividends
Year Total Dividends
2027
2.85 EUR
Aug. 19, 2027 (estimated) 0.9572
Feb. 18, 2027 (estimated) 1.8943
2026
2.79 EUR
Aug. 6, 2026 0.9269
Feb. 19, 2026 1.8596
2025
2.85 EUR
Aug. 7, 2025 0.8942
Feb. 20, 2025 1.9587
2024
2.72 EUR
Aug. 8, 2024 0.9047
Feb. 22, 2024 1.8188
2023
2.74 EUR
Aug. 10, 2023 0.8371
Feb. 23, 2023 1.8981
2022
2.58 EUR
Aug. 11, 2022 0.8907
Feb. 24, 2022 1.6941
2021
2.36 EUR
Aug. 12, 2021 0.7555
Feb. 25, 2021 1.6019
2020
2.52 EUR
Aug. 13, 2020 0.8115
Feb. 27, 2020 1.7069
2019
2.55 EUR
Aug. 8, 2019 0.8383
Feb. 28, 2019 1.7115
2018
2.36 EUR
Aug. 9, 2018 0.7975
Feb. 15, 2018 1.5576
2017
2.43 EUR
Aug. 10, 2017 0.8033
Feb. 16, 2017 1.6308
2016
2.40 EUR
Aug. 11, 2016 0.7725
Feb. 18, 2016 1.6308
2015
2.40 EUR
Aug. 13, 2015 0.7725
Feb. 19, 2015 1.6308
2014
2.40 EUR
Aug. 13, 2014 0.7725
Feb. 19, 2014 1.6308
2013
2.49 EUR
Aug. 14, 2013 0.8583
Feb. 13, 2013 1.6308
2012
2.63 EUR
Aug. 8, 2012 0.7725
Feb. 15, 2012 1.8597
2011
2.57 EUR
Aug. 3, 2011 0.8106
Feb. 2, 2011 1.7643
2010
2.30 EUR
Aug. 4, 2010 0.6676
Feb. 3, 2010 1.6308
2009
1.99 EUR
Aug. 5, 2009 0.5627
Feb. 4, 2009 1.4305
2008
1.81 EUR
Aug. 6, 2008 0.5245
Feb. 6, 2008 1.2875
2007
1.67 EUR
Aug. 8, 2007 0.4959
Feb. 7, 2007 1.1730
2006
1.34 EUR
Aug. 9, 2006 0.4673
Feb. 8, 2006 0.8774
2005
0.98 EUR
Aug. 15, 2005 0.3624
Feb. 9, 2005 0.6151
2004
0.74 EUR
Aug. 11, 2004 0.2813
Feb. 18, 2004 0.4635
Upcoming Dividends
Name Payment Date Status Amount
AstraZeneca PLC Aug 06, 2026 0.926891 EUR
AstraZeneca PLC Feb 19, 2026 1.859611 EUR
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion